Trial Profile
A 52-Week, 2-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy, and Safety Study of 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2013
Price :
$35
*
At a glance
- Drugs Cerlapirdine (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 06 Jun 2012 Actual patient number 526 added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Actual patient number 526 added as reported by ClinicalTrials.gov.
- 10 Aug 2011 Planned end date changed from 1 Sep 2011 to 1 May 2011 as reported by ClinicalTrials.gov.